Literature DB >> 23040735

Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study.

Phoebe V Kahn1, Trina M Walker, Teresa S Williams, Barbara A Cornblatt, Richard C Mohs, Richard S E Keefe.   

Abstract

BACKGROUND: The Continuous Performance Test (CPT) has emerged as the most commonly administered measure of sustained attention, but use of discrepant versions reduces the ability of researchers and clinicians to accurately draw cross-study conclusions. In an effort to standardize use of the CPT, this study compared four versions of the Identical Pairs CPT for their reliability and ability to discriminate between patients with schizophrenia and healthy volunteers. The relationship of performance on the different versions of the CPT with measures of psychopathology, functioning, and other aspects of cognition was also examined.
METHODS: Performance on the 2-digit, 3-digit, 4-digit, and Shapes Identical Pairs CPT was assessed at three test sessions over five weeks, during which subjects also completed the Brief Assessment of Cognition in Schizophrenia (BACS) and questionnaires assessing psychopathology and functioning.
RESULTS: All four CPTs discriminated between patients with schizophrenia and healthy volunteers, but there were no statistical differences in sensitivity among the versions. The 3-digit CPT showed non-statistical advantages in that it had high test-retest reliability, low potential for a ceiling effect, and a very low rate of false alarms. There were also moderate correlations between CPT performance and performance of the BACS subtests, but no significant correlations between CPT performance and measures of psychopathology and functioning.
CONCLUSIONS: While all versions of the CPT tested here had good psychometric characteristics, the 3-digit CPT-IP has some advantages in repeated measures studies such as clinical trials.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23040735     DOI: 10.1016/j.schres.2012.09.009

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  8 in total

1.  Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis.

Authors:  Emma Yong; Mariapaola Barbato; David L Penn; Richard S E Keefe; Scott W Woods; Diana O Perkins; Jean Addington
Journal:  Psychiatry Res       Date:  2014-04-12       Impact factor: 3.222

2.  Neurocognitive pattern analysis reveals classificatory hierarchy of attention deficits in schizophrenia.

Authors:  Christina Shen; Florin C Popescu; Eric Hahn; Tam T M Ta; Michael Dettling; Andres H Neuhaus
Journal:  Schizophr Bull       Date:  2013-08-10       Impact factor: 9.306

3.  Assessing long-term test-retest reliability of the CPT-IP in schizophrenia.

Authors:  Eric Hahn; Andrea Vollath; Tam T M Ta; Constanze Hahn; Linn K Kuehl; Michael Dettling; Andres H Neuhaus
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

4.  Preclinical characterization of AMPA receptor potentiator TAK-137 as a therapeutic drug for schizophrenia.

Authors:  Maiko Tanaka; Akiyoshi Kunugi; Atsushi Suzuki; Noriko Suzuki; Motohisa Suzuki; Haruhide Kimura
Journal:  Pharmacol Res Perspect       Date:  2019-05-09

5.  Severity in sustained attention impairment and clozapine-resistant schizophrenia: a retrospective study.

Authors:  An-Sheng Lin; Hung-Yu Chan; Ying-Chieh Peng; Wei J Chen
Journal:  BMC Psychiatry       Date:  2019-07-12       Impact factor: 3.630

6.  A mouse model of the 15q13.3 microdeletion syndrome shows prefrontal neurophysiological dysfunctions and attentional impairment.

Authors:  Simon R O Nilsson; Pau Celada; Kim Fejgin; Jonas Thelin; Jacob Nielsen; Noemí Santana; Christopher J Heath; Peter H Larsen; Vibeke Nielsen; Brianne A Kent; Lisa M Saksida; Tine B Stensbøl; Trevor W Robbins; Jesper F Bastlund; Timothy J Bussey; Francesc Artigas; Michael Didriksen
Journal:  Psychopharmacology (Berl)       Date:  2016-03-17       Impact factor: 4.530

7.  Reverse translated and gold standard continuous performance tests predict global cognitive performance in schizophrenia.

Authors:  Andrew W Bismark; Michael L Thomas; Melissa Tarasenko; Alexandra L Shiluk; Sonia Y Rackelmann; Jared W Young; Gregory A Light
Journal:  Transl Psychiatry       Date:  2018-04-12       Impact factor: 6.222

8.  Assessing the Cognitive Translational Potential of a Mouse Model of the 22q11.2 Microdeletion Syndrome.

Authors:  Simon Ro Nilsson; Kim Fejgin; Francois Gastambide; Miriam A Vogt; Brianne A Kent; Vibeke Nielsen; Jacob Nielsen; Peter Gass; Trevor W Robbins; Lisa M Saksida; Tine B Stensbøl; Mark D Tricklebank; Michael Didriksen; Timothy J Bussey
Journal:  Cereb Cortex       Date:  2016-08-09       Impact factor: 5.357

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.